1.AZD9291-induced Acute Interstitial Lung Disease.
Ke-Ke NIE ; Xiao ZOU ; Chuan-Xin GENG ; Ling ZHANG ; Shi-Chao LIU ; Chun-Ling ZHANG ; You-Xin JI
Chinese Medical Journal 2016;129(12):1507-1508
2.Two Cases of Interstitial Pneumonitis Caused by Rituximab Therapy.
Yuna LEE ; Sun Young KYUNG ; Soo Jin CHOI ; Soo Mee BANG ; Seong Hwan JEONG ; Dong Bok SHIN ; Jae Hoon LEE
The Korean Journal of Internal Medicine 2006;21(3):183-186
Rituximab, a chimeric monoclonal antibody directed against CD20, has become a part of the standard therapy for patients with non-Hodgkin's lymphoma either in combination with other drugs or as a single agent. The CD20 antigen is expressed on 95% of B-cell lymphoma cells and normal B-cells but, is not found on precursor B-cells or stem cells. Rituximab is now approved for patients with diffuse large B-cell lymphoma when combined with standard CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and prednisone) or patients with follicular lymphoma who have failed first line chemotherapy. The monoclonal antibody is generally well tolerated. Most of the adverse events are infusion-associated, mild to moderate non-hematological toxicities. Severe respiratory adverse events have been infrequent. Here, we report two patients with non-Hodgkin's lymphoma in whom interstitial pneumonitis developed with rituximab therapy.
Prednisolone/therapeutic use
;
Methylprednisolone/therapeutic use
;
Male
;
Lung Diseases, Interstitial/*chemically induced/diagnosis/drug therapy
;
Humans
;
Antineoplastic Agents/*adverse effects
;
Antibodies, Monoclonal/*adverse effects
;
Aged
3.Severe acute interstitial lung disease induced by crizotinib therapy in a patient with c-Met amplification non-small cell lung cancer.
Youxin JI ; Zhongfa ZHANG ; Keke NIE ; Ketao LAN ; Chuanxin GENG ; Shichao LIU ; Ling ZHANG ; Zongchun ZHANG ; Lei SUN ; Xiao ZOU
Chinese Medical Journal 2014;127(8):1600-1600
4.Acute interstitial pneumonia caused by interleukin-2 and interferon α-2b therapy for renal cell carcinoma: a case report and clinical study.
Chinese Medical Journal 2014;127(23):4154-4156
Aged, 80 and over
;
Carcinoma, Renal Cell
;
drug therapy
;
Female
;
Humans
;
Interferon-alpha
;
adverse effects
;
therapeutic use
;
Interleukin-2
;
adverse effects
;
therapeutic use
;
Lung Diseases, Interstitial
;
chemically induced
;
diagnosis
;
Recombinant Proteins
;
adverse effects
;
therapeutic use
5.Imatinib mesylate-induced interstitial lung disease in a patient with prior history of Mycobacterium tuberculosis infection.
Na Ri LEE ; Ji Won JANG ; Hee Sun KIM ; Ho Young YHIM
The Korean Journal of Internal Medicine 2015;30(4):550-553
No abstract available.
Adult
;
Antineoplastic Agents/*adverse effects
;
Antitubercular Agents/therapeutic use
;
Biopsy
;
Female
;
Gastrointestinal Stromal Tumors/*drug therapy/pathology/surgery
;
Humans
;
Imatinib Mesylate/*adverse effects
;
Lung Diseases, Interstitial/*chemically induced/diagnosis
;
Mycobacterium tuberculosis/*isolation & purification
;
Protein Kinase Inhibitors/*adverse effects
;
Rectal Neoplasms/*drug therapy/pathology/surgery
;
Tomography, X-Ray Computed
;
Tuberculosis, Pulmonary/diagnosis/drug therapy/*microbiology
Result Analysis
Print
Save
E-mail